StemCell Therapy

June 20, 2017

Results were analyzed for early intervention in 1156 patients with pre-RA, at 52 weeks

Early treatment intervention in patients with "pre-rheumatoid arthritis" (pre-RA) significantly lowered the risk of RA occurrence in patients at 52 weeks and beyond. The full findings of the meta-analysis were presented at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid, Spain.

Pre-RA is defined as undifferentiated arthritisor very early RA, a point where early intervention could be more effective. Study authors searched PubMed, Embase, and Cochrane databases as well as the EULAR and ACR congress abstracts. They identified two congress abstracts and nine randomized controlled trials: eight of which were related to undifferentiated arthritis, and one which was related to very early RA.

Of the total patient sample (n=1,156), the majority were female and the mean symptom duration was 16.2 weeks. Early intervention in these pre-RA patients included methylprednisolone, methotrexate, TNF-blockers, abatacept or rituximab. Findings from the review showed a significant reduction in the risk of RA occurrence at 52 weeks or more "although there was no statistically significant difference in the absence of disease progression as seen on X-ray between those taking active treatments or placebo due to the disease being at such early stage," noted lead author Dr. Stephane Hilliquin, from the Piti Salptrire University Hospital, Paris, France.

The authors concluded that the literature review of the available data supports the rationale for early intervention in these patients. The benefit to risk profile and the feasibility of early treatment of pre-RA in clinical settings still warrant further research.

For more information visit eular.org.

Excerpt from:
Early Treatment of 'Pre-RA' Patients May Reduce Risk of Rheumatoid Arthritis - Monthly Prescribing Reference (registration)

Sigillo Cellars owner and head winemaker, Mike Seal, right, presented a check representing 10 percent of Sigillos sales of Sauvignon Blanc in May, to Arthritis Foundation Development Manager Toni Arrowsmith, left, and Arthritis Foundation Senior Executive Director Kelsey Woods. Courtesy Photo

In connection with Arthritis Awareness Month, Sigillo Cellars in Snoqualmie has donated 10 percent of all its sales of the winerys first-release Sauvignon Blanc in May to the Arthritis Foundation. Sigillo Cellars owner Mike Seal recently presented a check for the donation to Senior Executive Director Kelsey Woods and Development Manager Toni Arrowsmith of the Washington Arthritis Foundation.

Mike expressed a big Thank You to all of our Club Members and guests who are enjoying Sigillo Cellars first Sauvignon Blanc release while supporting an organization that provides resources for the 1.2 million adults and 6,000 children in Washington State managing life with Arthritis.

picture: (left) Toni Arrowsmith, Development Manager, Arthritis Foundation, (middle) Kelsey Woods, Senior Executive Director, Arthritis Foundation, (right) Mike Seal, Owner and Head Winemaker, Sigillo Cellars

Go here to read the rest:
Sigillo Cellars donates part of Sauvignon Blanc sales to Arthritis Foundation - Snoqualmie Valley Record

A new study confirms the link between active smoking and the risk of developing rheumatoid arthritis (RA). It also suggests, for the first time, that smokers who had early life exposure to tobacco through passive smoking have a significantly increased risk for developing the disease.

RA is the most common chronic inflammatory joint disease, causing progressive joint destruction, disability and reduced life expectancy. In recent years, many potential environmental factors have been associated with an increased risk of developing RA, but so far smoking is the only one that has been extensively studied.

The findings were recently presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference.

For the study, a large population of female volunteers born between 1925 and 1950 were tracked beginning in 1990. Out of 70,598 women, a total of 1,239 patients self-reported developing RA, of which 350 cases were eligible for analysis of the link to active and passive smoking. The mean age at inclusion in the study was 49.0 years; the mean duration of follow-up was 21.2 years.

Between 1990 and 2014, 11 self-administered questionnaires were sent to the participants to collect medical, demographic, environmental and hormonal data and dietary habits. The diagnosis of RA was collected on two successive questionnaires.

Cases were considered certain if, having reported RA, they had taken an RA specific medication (methotrexate, leflunomide or a biologic) since 2004 (the period from which drug reimbursement data was available). Participants were excluded if they had an inflammatory bowel disease and/or no information on their smoking status.

Passive smoking was assessed by the following question: When you were children, did you stay in a smoky room? Patients were considered exposed if the answer was yes, a few hours, or yes, several hours a day.

The findings show that passive smoking exposure during childhood increased the association between RA risk and adult active smoking.

Our study highlights the importance of avoiding any tobacco environment in children, especially in those with a family history of RA, said lead author Professor Raphale Seror from University Hospitals of South Paris, France.

In addition, the preliminary results of a meta-analysis reveal that smoking is also related to an increased progression of structural damage to the spine in patients with ankylosing spondylitis (AS), a form of arthritis that affects the spine.

Smoking constitutes a major risk factor not only for disease susceptibility but also disease severity in patients with AS, said lead author Professor Servet Akar from Izmir Katip Celebi University Faculty of Medicine in Turkey.

Rheumatologists should work hard to encourage their AS patients to quit smoking as this could have a major impact on future quality of life.

Source: European League Against Rheumatism

APA Reference Pedersen, T. (2017). Passive Smoking in Childhood Can Hike Risk of Arthritis in Adult Smokers. Psych Central. Retrieved on June 19, 2017, from https://psychcentral.com/news/2017/06/19/passive-smoking-in-childhood-significantly-ups-risk-of-arthritis-in-adult-smokers/122071.html

Continued here:
Passive Smoking in Childhood Can Hike Risk of Arthritis in Adult Smokers - PsychCentral.com

Peter Boyd Author living with arthritis

LIVING WITH ARTHRITIS for the rest of my life is one thing. Accepting that Ill never work again is quite another.

If I manage my rheumatoid arthritis correctly I potentially have 40 years of contributing in the workplace ahead of me. If Im passive and leave the arthritis in control I could have 40 years of benefits and disability payments.

Even doing the right thing and fighting arthritis with all my energy, what little I have these days, is no guarantee Ill be able to work again but Ive got to try. The only thing that is certain in the crazy, changed, unplanned for, painful, tiring, exhausting, soul destroying, exciting, medicated, drowsy, financially insecure arthritis world is that Ill fight it.

Im seven years into my journey. Im the man who spoke on behalf of Arthritis Ireland recently and said: I stand before you 33 years old, grateful for the day I got arthritis.

Being diagnosed

Thats skipping past a few chapters in my story, let me fill in the gaps.

In 2011, I was working as a full-time barman. On a quiet evening after a rugby match I began chatting to two regulars over the taps.Then I fell asleep.

Mid-conversation, mid-pub, mid-shift, I fell asleep. This was the final straw in work. I couldnt get bottles from the bottom shelf, carry a crate of beer, change kegs, stand for my entire shift or take deliveries.I was no longer a barman. I sat down with the bosses and took two weeks holiday. I never went back to work.

I lost my job and my financial security but had a mortgage to pay. I had appointments with every specialist in the hospital because RA is an auto-immune condition and the inflammation affected my whole body and every system in it.

Saying no to going out with my friends led them to stop asking. With no job, no money, lots of pain and overwhelming fatigue I lost my self-confidence and self-worth. Once they went, I stopped wanting to go out at all, saw no point in minding myself.

The inevitable depression

Depression was almost inevitable some might say. I fell into a deep, ongoing, depression that I continue to battle with every day. Ive had awful days when it all seemed too much. If Im honest, I still do.

My turnaround has been a huge success though and Ive done a lot of hard work to make it so. The impetus came from my family and Arthritis Ireland however.

My family have always provided the perfect blend of support and tough love, depending on the circumstance. When I needed a kick I got it but when I needed to be coaxed and cajoled I got that too.

Meeting people in the same boat as me opened doors I never knew existed when I did my Leisure Management Degree, worked as a barman and acted like the selfish person I was.

Arthritis Ireland introduced me to children, teenagers and adults of all ages living with their form of arthritis. I did the self-management course, trained to be on the helpline and, in helping others, I boosted myself. Im now on the Board of Directors of Arthritis Ireland.

Im a better person now

Ive learnt skills I wouldnt have done without arthritis. Two years ago, my confidence had been restored enough to go back into the classroom. Ive finished studying in Dun Laoghaire Further Education Institute and have a Higher Certificate in my pocket.

It was vital I retrained. Arthritis Ireland, my family and my friends helped rebuild my confidence to a point where I could upskill and find a new career path.

So while its awful, Im in more pain than ever and I hate having to inject myself every week, I am grateful for arthritis.

Im a better person than I was before my diagnosis and Ive learnt so many things. Im now an intern with Cricket Ireland at one of the most exciting, and potentially historic, times for the game in this country.

I dont wish my life had taken any other path and thats the honest truth.

Peter Boyd, the second of four siblings, lives in Balbriggan, North County Dublin. Though not as active as he used to be, he is still passionate about watching live sport as much as possible. Healso has huge interest in history and writing, and is a published author, having self-published his first novel in 2016.The RA NarRAtive patient survey was conducted by Harris Poll on behalf of Pfizer via an online survey that was distributed by local patient advocacy groups (PAGs) between March 20 April 6, 2017 among 211 adults, ages 18+, who have been diagnosed with rheumatoidarthritis(RA) in Ireland.ArthritisIreland is Irelands only organisation working to provide information and support for people witharthritis.For more information onArthritisIreland visitwww.arthritis.ie.

Get breaking news from TheJournal.ie via Facebook. Just click Like.

The rest is here:
Arthritis: 'I am grateful for arthritis. I'm a better person than before my diagnosis' - thejournal.ie

Consumer Update

Per the CDC, 23 percent of Americans suffer from arthritis, a leading cause of disability among adults in the U.S. Some of those afflicted seem to think that their only solutions for relieving pain are medication and surgery.

Dr. Arthritis is a company founded by a group of doctors looking to change that outlook. These are doctors with intimate knowledge of patients and the rheumatological and orthopedic conditions they suffer from.

With their line of products aimed at arthritis and other joint conditions, they offer a solution to relieve discomfort and pain.

Products include gloves and sleeves for hands, elbows, knees, cuffs, ankles, and feet. Infused with copper and through the use of compression, they help to reduce swelling and pain, while offering much-needed support.

Having worked with patients for many years and seeing the impact that arthritis has on a persons life helped Doctor Arthritis achieve the goal to help as many arthritic individuals as possible. Alongside their joint compression products, each of their customers receives a The Dr. Arthritis Handbook containing specific information on the condition, treatments, and exercises for the joint or muscle affected by arthritis.

The compression gloves infused with copper are developed with consideration and care towards each and every patient. Each glove or sleeve comes with a doctor written handbook outlining all the basic information patients should know about the joint affected.

This outlines the various conditions as well as exercises for strengthening joints and advice on lifestyle measures to improve symptoms

By offering products to help relieve symptoms while also educating, those who suffer from arthritis and other joint conditions are put back in the drivers seat. Doctor Arthritis has a passion for helping patients achieve a good, pain-free life.

For more information or to read their weekly blog visit doctorarthritis.org today.

Continue reading here:
Doctor Arthritis Clothing Products for Arthritic Individuals | NewsWatch Review - NewsWatch

Arthritis affects more than ten million people and it takes over lives.

The crippling condition can cause severe mobility problems, make sleeping impossible and turn basic tasks into a mission.

But instead of relying on anti-inflammatories and painkillers, which have been linked to stomach and heart issues, the Sunday People can reveal there are alternatives.

And they could even stop you developing it in the first place.

Chemicals found in the exotic fruits can protect against osteoarthritis the most common form of arthritis .

Called phytochemicals, they help prevent damage to cartilage cells, which keeps bones healthy.

Pomegranate seeds are also full of punicic acid, which has powerful antioxidant properties and could reduce joint inflammation.

Eating more fruit, veg, beans, whole grains, olive oil and fatty fish may help tackle the disease and increase mobility.

The first study into the link between a Mediterranean diet and osteoarthritis recently found that eating more of these ingredients over a 16-week period helped reduce inflammation and maintain bone health.

Run by charity Arthritis Action, the research saw the inflammatory blood biomarker of participants drop by almost half, while a cartilage degeneration dropped 8 per cent. The experts also recommended cutting down on red meat.

It is important to keep muscles and joints moving, even if you do not have arthritis.

Moderate exercise has even been found to help prevent osteoarthritis in the knees and hips physical activity helps lubricate the joints and maintain cartilage elasticity.

While running had previously been thought to be bad for joints, a study recently found that regular jogs are good news for the knees and hips and can cut your osteoarthritis risk.

But researchers for the study, published in the Journal of Orthopaedic and Sports Physical Therapy, say overdoing it could do more harm than good.

Stationary cycling, known as spinning, is good for the knees.

Researchers at Northern Illinois University found it is the best exercise to get people with mild-to-moderate symptoms back on their feet.

If you are looking for more of a relaxed exercise regime, try tai chi.

The Chinese practice has been linked to reduced pain, fatigue and stiffness, plus improved mobility in people with osteoarthritis.

The slow breathing and gentle movements boost muscle strength and balance.

After six weeks, participants in a University of Miami study were able to walk faster and further.

Pulsed electromagnetic field therapy is providing an alternative to anti-inflammatories and painkiller medication.

The clever tech is in a wearable device and involves an electrically charged magnet delivering energy to the painful area.

Patients with osteoarthritis who used the gadget for 12hours a day over one month saw their pain greatly reduced, according to a study in Rheumatology journal. And some even came off painkillers completely.

Link:
Six ways to help you battle arthritis AND ward off painful condition - Mirror.co.uk

Shreveport, LA -- Juvenile Arthritis is a condition no child and their family should have to go through.

That's why rheumatoid arthritis doctor Tom Pressly started Jambalaya Jubilee to help children and the families get the latest on medicine in their field and also meet others like themselves. The children also get to do fun activities at the family retreat together like arts and craft, bowling, and visiting facilities like Sci-Port.

This year is the 27th annual Jambalaya Jubilee and 44 families were a part of the program.

Saturday morning, they were visited by Kansas City Chiefs player Charcandrick West who also had juvenile rheumatoid arthritis. He says he was once bedridden by the pain, but Dr. Pressly helped him find a cure.

Today West told the children in the camp that no dream is too big for them and that they shouldn't let anyone discourage them from following it.

West says it's a blessing for him to be able to meet with the kids and see them fight their illness.

Both West and Dr. Presssly hope the camp encourages the children to lead their lives and follow their dreams. Pressly also hopes families see that they aren't alone in their struggle and their children can still lead normal lives.

See original here:
Camp for children with arthritis gets visited by NFL player - KTBS

While much of the Western world is only just beginning to embrace the notion of medical marijuana for humans, theres an even more controversial debate lurking right around the corner hasanyone thought about giving their pet a strong dose of pot?

Immediately, images of dogs with great big marijuana joints hanging out of their mouths jump into your mind. Or perhaps a cute little kitten taking a good long drag on a bong and going into a fit of cute kitten coughs. While its a slightly hilarious mental picture, its obviously not accurate how the heck would you get them to inhale the smoke anyway? Smoke a joint yourself and blow it into their face?

But beyond the practical (and ethical) dilemma such a scene represents, theres another reason why your pet isnt going to be ingesting marijuana: its not marijuana that theyre ingesting! Not the kind that you became familiar with in your rebellious teenage years, anyway.

Hemp contains CBD, responsible for multiple health-promoting effects.

Lets get one thing straight: hemp and marijuana are, indeed, the same species. Theres actually a lot of misconceptions surrounding what exactly hemp is, with many people thinking theyre either completely separate species, or that hemp is the male variety of Cannabis sativa and marijuana the female.

The truth is, hemp and marijuana are simply different cultivars of the exact same species. While marijuana contains high levels of THC, the cannabinoid that creates that mind-altering high, hemp is required by law to have a THC concentration of 0.3 percent or less. Also, depending on the specific cultivar, hemp often contains higher levels of the therapeutic active compound cannabidiol (CBD), which is responsible for almost all of Cannabis sativas health-promoting effects.

For this reason, most of the cannabis products on the market aimed at pets are in fact hemp, as this still elicits the therapeutic effects on your pet but doesnt get them staring vacantly at the TV or eating everything in sight. The exception, of course, is those products specifically formulated for treating pet anxiety. In this case, a strong dose of THC from good old marijuana is just the ticket.

The short answer is: maybe. Theres a growing body of evidence to confirm that medical marijuana (and indeed hemp) has a huge range of beneficial effects on the body and mind of us humans. You can take your pick of the therapeutic powers of marijuana: cancer treatment, pain-alleviating, reduction in multiple sclerosis symptoms, epilepsy treatment and of course as an antidepressant.

And while our physiology may differ considerably from that of our pets, there are enough similarities to confirm that many of these same therapeutic effects of marijuana can also be experienced by our animals. Unfortunately, because its an emerging field, theres not as much scientific evidence as one would like. But, what studies have been completed show a lot of promise. And there are the thousands of anecdotal case studies from pet owners all over the world to consider.

But before we dive any deeper, its important to emphasize that every pet is different. As you well know, they come in all shapes and sizes, from tiny little birds to Great Danes or even horses. For each species and indeed each breed, the dosage is always going to be different, meaning you should consult your vet before starting your problematic pet on a course of cannabis.

So, why should you give your pet marijuana to treat his or her health problems? Lets find out.

Multiple studies have shown that CBD can treat arthritis, and it may be true for your pet too.

Many holistic vets across the country are recommending medical marijuana for the treatment of arthritis in certain animals, including cats and dogs. They maintain that the potent anti-inflammatory compounds in marijuana and hemp, largely in the form of CBD, can provide significant relief from pain in arthritic pets and enable them to have fuller, more enjoyable lives.

And theres plenty of research out there, admittedly mostly conducted on rats and mice, that supports these veterinary claims. A study published in 2000 in the journal PNAS used a concentrated form of CBD (which youll recall is found in high concentrations in hemp, and to a lesser extent marijuana) to treat two different forms of arthritis in mice. They found that in both models of arthritis, the treatment effectively blocked progression of arthritis.

Another study, this time published in 2004, examined the therapeutic effect that CBD exhibited on rats that had been injected with inflammation-causing and arthritis-inducing carrageenan. Researchers concluded that the CBD had significant beneficial effects on many different markers of both inflammation and arthritis.

For this reason, using medical marijuana, hemp or a high-quality cannabidiol (CBD) treatment can provide good levels of relief for your pet, especially cats, dogs and (apparently) rats and mice. Combining CBD treatment with other holistic treatments, like massage, acupuncture (yup, acupuncture for pets is a thing!) and fish oil, can increase your chance of success.

Inflammatory bowel disease is a surprisingly common affliction in pets, particularly cats. By reducing inflammation, its possible that the CBD in marijuana may help to alleviate symptoms of IBS. By soothing their gastrointestinal tract, the CBD will also allow them to regain a healthy weight and be more enthusiastic about eating. Perhaps a little too enthusiastic at times!

CBD may promote feelings of calm for your anxious pet.

Just as it is in humans, anxiety is a very real problem in many pets. Our cat, Ollie, had all sorts of problems with anxiety, stemming from a very troubled kittenhood as an abandoned street cat. While we were able to soothe much of those anxieties away over years of TLC, he still suffered form serious bouts of anxiety from time to time, particularly when lightning storms rolled in across the lake. The last time this happened, he actually suffered from a complete urinary tract blockage, and we spent many hundreds of dollars and a harrowing week trying to bring him back from the brink with various drugs and anti-anxiety medications.

The CBD in medical marijuana has the ability to almost instantaneously foster feelings of tranquility and calm in pets, thereby helping them to overcome their anxiety. And while I dont recommend regular use of marijuana to calm their frayed nerves, in scenarios like our beloved Ollies case, it may be a life-saving move.

Liivi Hess

Tweet

Share

Tags: anxiety, arthritis, cannabis, cats, CBD, dogs, hemp, ibs, inflammation, marijuana, medical marijuana, pets, pot, THC, weed

Read more from the original source:
Should You Give Your Pet Medical Marijuana For Arthritis? - The Alternative Daily (blog)

June 16, 2017

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).

New agents working on different inflammatory aspects of PsA are needed in the treatment of PsA patients living with this chronic immune-mediated disease, which involves both joint and skin symptoms.

In the first study, in patients with active PsA who had not previously been prescribed an anti-TNF treatment, tofacitinib (an oral Janus kinase inhibitor under investigation for the treatment of PsA), was superior to placebo in ACR20 response rates and change from baseline in the HAQ-DI score at 3 months. Tofacitinib demonstrated superiority to placebo as early as week 2, and this was maintained for 12 months. No new safety risks were identified compared to previous studies in other indications.1

In the second study, in patients with active PsA and 3% or more of their body surface area affected by plaque psoriasis despite current or previous treatment with standard-of-care therapies, including anti-TNF treatments, guselkumab demonstrated significant improvement in joint symptoms, physical function, psoriasis, enthesitis , dactylitis and quality of life. Guselkumab, a fully human monoclonal antibody targeting IL-23, in this Phase 2 study for the treatment of PsA, was well tolerated with no unexpected safety findings in this patient population.2 Guselkumab is now being pursued in a Phase 3 development programme for psoriatic arthritis.

Tofacitinib Phase 3 Results positive for treating PsA

At month 3, tofacitinib 5 and 10 mg twice-daily showed a statistically significant improvement compared to placebo as measured by the ACR20 response (p?0.05 and p<0.0001 respectively), and change from baseline in the HAQ-DI score (p?0.05 and p<0.001).

"Despite the differences emerging in the pathophysiology of PsA and rheumatoid arthritis, tofacitinib, which works on many different cytokines, shows efficacy in the treatment of both conditions," said lead author Professor Philip J. Mease from the Swedish-Providence St. Joseph Health Systems and University of Washington School of Medicine, Seattle, US. "Since tofacitinib is a tablet and not an injection, once it receives regulatory approval, it is likely to be popular with both physicians and patients," he added.

Tofacitinib 5 and 10 mg twice-daily was superior to placebo for ACR20 response rates at week 2 (p<0.001 and p<0.0001 respectively) with responses maintained to 12 months. Greater efficacy was also seen for adalimumab vs. placebo.

More than 91% of patients were radiographic non-progressors at 12 months. Safety findings were similar between the treatment groups at 12 months. The most common adverse events were upper respiratory tract infection (7.5-10.6%), nasopharyngitis (7.5-11.5%) and headache (3.8-10.6%).

Eligible patients in this randomised, placebo- and active-controlled, 12-month Phase 3 trial had a PsA diagnosis for at least 6 months, fulfilled CASPAR criteria , had active arthritis (at least 3 tender/painful and at least 3 swollen joints) and active plaque psoriasis at screening, inadequate response to at least 1 csDMARD , and were tumour necrosis factor-inhibitor (TNFi)-nave.

422 patients were randomised 2:2:2:1:1 to tofacitinib 5 or 10 mg twice daily, adalimumab 40 mg subcutaneous injection every 2 weeks, or placebo (advancing to tofacitinib 5 or 10 mg twice-daily at 3 months). Stable treatment with 1 csDMARD was required. 96.9% of patients were white and 53.3% were female; mean age was 47.9 years. 96.2% and 88.4% of patients completed 3 and 12 months respectively.

Guselkumab improved PsA symptoms, physical function and quality of life

In this Phase 2a study, significantly more guselkumab-treated patients achieved ACR 20/50/70 responses and Psoriasis Area Severity Index (PASI) 75/90/100 responses at week 24. Nearly 40% of patients in the active group, vs. 6.3% in the placebo arm, achieved PASI 100 (completely clear skin) at week 24.

"Guselkumab, which targets IL-23, appears to be a promising new treatment of PsA," said lead author Professor Atul Deodhar from Oregon Health & Science University, Portland, US. "Although anti-TNF treatments have revolutionised the management of psoriatic arthritis, new next-generation therapies are needed in the treatment of this disease," he added.

As early as 4 weeks into treatment, 21% in the guselkumab group had a significant treatment effect on ACR20 response, compared to zero in the placebo group (p<0.001). The ACR response in the active arm increased with time, with 58% of subjects reaching a 20% improvement in joint symptoms at week 24, versus 18.4% of those on placebo (p<0.001). Fourteen percent of patients on guselkumab achieved ACR70, versus 2% on placebo, at week 24 (p=0.023).

Resolved enthesitis occurred in 29.0% of those patients with enthesitis at baseline in the placebo group at week 24, versus 56.6% on guselkumab (p=0.012). The percentage resolution from baseline to week 24 for dactylitis (in those patients with dactylitis at baseline) was 17.4% of patients on placebo, versus 55.2% on guselkumab (p<0.001). And the percentage of patients achieving minimal disease activity at week 24 was 2% for placebo compared to 23% in the guselkumab group (p=0.001).

Patients in the active arm also seemed to experience mental benefits, with significantly higher scores on the SF-36 mental component summary (p=0.002), in addition to significantly higher physical component scores (p<0.001).

Guselkumab was well tolerated; through week 24, the proportion of patients with at least 1 adverse event was comparable between the two groups (guselkumab 36.0% vs. placebo 32.7%). Infections were the most common adverse events (guselkumab 17.0% vs. placebo 20.4%). The researchers reported no serious infections, cancer or death during the 24 weeks of the study.

This Phase 2a, randomised, double-blind, placebo-controlled multicentre study included 149 active PsA patients. Patients had psoriasis plaques covering three percent or more of their body surface area, despite standard-of-care treatment, which in some patients included anti-TNF agents. In a 2:1 ratio, patients received either 100 mg guselkumab given subcutaneously, or placebo at baseline and week four; then, every eight weeks through week 44.

Patients in both arms who had less than a 5 percent improvement from baseline in swollen and tender joint counts by week 16 could qualify for early escape and switch to open-label therapy with ustekinumab. All remaining placebo patients crossed over to the guselkumab arm at week 24.

Baseline demographics and ACR component measures were generally similar between the two groups. Four (8.2%) of the patients in the placebo group and 9 (9.0%) of patients in the guselkumab group had been previously exposed to an anti-TNF agent

Explore further: Tofacitinib ups rheumatoid arthritis treatment response

(HealthDay)The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have highlighted limitations in the current treatment of patients with Psoriatic Arthritis (PsA).

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses ...

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent ...

In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

The results of a study led by Massachusetts General Hospital (MGH) investigators suggest that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout. The team's ...

In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
New effective treatments for psoriatic arthritis patients - Medical Xpress - Medical Xpress

June 16, 2017

The studys primary endpoint was an improvement in arthritis signs and symptoms

Janssenannounced results from the Phase 3 study, GO-VIBRANT, evaluatingSimponi Aria(golimumab) for the treatment of active psoriatic arthritis. The results were presented at the 2017 Annual European Congress of Rheumatology (EULAR) in Madrid, Spain.

GO-VIBRANT, a multicenter, double-blind, placebo-controlled trial, evaluated the safety and efficacy of intravenous Simponi Aria in biologic-nave adult patients withactive psoriatic arthritis. Patients (n=480) were randomized to receive Simponi Aria 2mg/kg at Weeks 0, 4, and every 8 weeks thereafter, or placebo at Weeks 0, 4, 12 and 20 with crossover to Simponi Aria at Week 24. The study's primary endpoint was an improvement in arthritis signs and symptoms as measured by the American College of Rheumatology ACR20 response at Week 14. Other endpoints of the trial included ACR50, ACR75, Psoriasis Area Severity Index (PASI 75) and mean change in HAQ-DI scores.

At Week 14, 75.1% of the treatment group achieved ACR20 vs. 21.8% of the placebo group, demonstrating a statistically significant benefit with Simponi Aria (P<0.001). A greater percentage of patients in the treatment arm compared with placebo achieved ACR50 (43.6% vs. 6.3%, respectively), ACR70 (24.5% vs. 2.1%) and PASI 75 (59.2% vs. 13.6%). The Simponi Aria group also experienced greater improvements in HAQ-DI scores from baseline to Week 14 (0.60) than placebo (0.12). All improvements in secondary endpoints with Simponi Aria were statistically significant withP<0.001.

Additionally, at Week 24, treatment with Simponi Aria showed significant inhibition of joint destruction and damage, joint erosion, and joint space narrowing compared to placebo.

Regarding adverse events, 46.3% of patients receiving Simponi Aria and 40.6% of patients receiving placebo reported at least one adverse event. The most common event was infection, which was seen in 20% of Simponi Aria-treated patients. No events of opportunistic infection or tuberculosis were reported throughout Week 24

Simponi Aria is a fully human anti-TNF-alpha monoclonal antibody that selectively targets TNF-alpha, a protein that causes inflammation and damages cartilage, tissue and bones. By inhibiting both soluble and transmembrane TNF-alpha, Simponi Aria helps control inflammation.

Simponi Aria is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate. It is available as single-use vials containing 50mg golimumab per 4mL of solution.

For more information visit SimponiAria.com.

Read the original here:
Golimumab Significantly Improves Psoriatic Arthritis Symptoms - Monthly Prescribing Reference (registration)

Please enable Javascript to watch this video

KANSAS CITY, Mo. --Charcandrick West, Chiefs running back, teamed up to make a music video with a little girl named Jillian Reid, age 10, because both of them have arthritis.

The music video is meant to raise awareness.

It features Charcandrick singing the song "Body of Steel". You can scroll down to watch and listen to the music video on YouTube.

Some of the lyrics:

We fight every day into the morning light We try to do the impossible. That's right. With every inch of pain, every scar.

One hand Holding onto another hand. One glance Telling me that I can try again and again. I know you got my back if I fall.

We can make it. Just look how far we've come. Everyday is a blessing...

Cause I got a body of steel I'm a fighter

One breath at a time One step at a time

More:
Music video about arthritis features Charcandrick West and 10-year-old singing partner - fox4kc.com

June 16, 2017

The trial included 363 patients with psoriatic arthritis

Eli Lilly reported that Taltz (ixekizumab) achieved primary and secondary endpoints in SPIRIT-P2, a Phase 3 clinical trial evaluating the treatment in psoriatic arthritis (PsA). These results were announced in the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid, Spain.

SPIRIT-P2, a randomized, double-blind, placebo-controlled study, evaluated the efficacy of Taltz in patients (n=363) with psoriatic arthritis who either exhibited inadequate response to one or two TNF inhibitors or were intolerant to TNF inhibitors. Patients were randomized to two treatment groups of Taltz or placebo for 24 weeks. The dosing regimens for Taltz treatment arms consisted of starting doses of subcutaneous (SC) Taltz 160mg then either 80mg SC once every 2 weeks or once every 4 weeks.

The primary endpoint of the study was the percentage of patients achieving at least a 20% reduction in disease activity as defined by the American College of Rheumatology (ACR20). Secondary endpoints measured included ACR50, ACR70, skin clearance defined by the Psoriasis Area Severity Index (PASI), and physical function assessed as change in HAQ-DI scores.

Both Taltz treatment arms showed significant superiority to placebo in achieving the primary endpoint of ACR20 (53% in patients treated every 4 weeks vs. 48% in patients treated every 2 weeks vs. 19% placebo;P<0.0001). Similar results of superiority were seen in comparison of ACR50 (35% and 33% vs. 5%, respectively;P<0.0001) and ACR70 (22% and 12% vs. 0%, respectively;P<0.0001).

Additionally, both Taltz regimens demonstrated significant improvements in skin clearance and HAQ-DI scores at Week 12 and Week 24 compared with placebo.

Treatment with Taltz resulted in greater treatment-emergent adverse events, which included injection site reaction, upper respiratory infection, nasopharyngitis and sinusitis. Other common adverse reactions established in previous trials were nausea and tinea infections.

Ixekizumab is a monoclonal antibody that selectively inhibits interleukin 17A (IL-17A), a cytokine responsible for inflammatory and immune responses. By inhibiting IL-17A, ixekizumab helps control excess inflammation.

Many patients with psoriatic arthritis have tried a variety of therapies and have either lost response over time, had an inadequate response or been intolerant of therapy, stated lead author of the study, Peter Nash, Associate Professor of the University of Queensland. If approved, ixekizumab may provide physicians with a new option in this difficult-to-treat patient population.

Taltz is filed under a supplemental Biologics License Application for the treatment of active PsA in adults. It is currently approved for the treatment of moderate to severeplaque psoriasisin patients who are eligible for systemic therapy or phototherapy.

The SPIRIT-P2 trial will continue to evaluate long-term efficacy and safety of Taltz in PsA for up to 3 years.

For more information visit Taltz.com.

View post:
Ixekizumab Effective in Psoriatic Arthritis After Inadequate TNFi Response - Monthly Prescribing Reference (registration)

June 16, 2017

The ORAL Strategy also compared tofacitinib alone vs. tofacitinib in combination with methotrexate

Pfizerannounced findings from the head-to-head Phase 3b/4 study comparingXeljanz (tofacitinib citrate; Pfizer) with or without methotrexate vs.Humira (adalimumab;AbbVie) with methotrexate for the treatment of moderate to severe rheumatoid arthritis. The ORAL Strategy also compared Xeljanz alone vs. Xeljanz in combination with methotrexate. Full findings were published in The Lancetand presented during the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid, Spain.

The non-inferiority study found that ACR50 response, the primary efficacy endpoint, was achieved in 46% of the Xeljanz 5mg twice daily + methotrexate group, 38.3% of the Xeljanz 5mg twice daily group, and in 43.8% of the Humira 40mg every other week + methotrexate group.

Study author, Dr. Roy Fleischmann, stated, "Although Xeljanz monotherapy did not demonstrate non-inferiority to either combination arm, the clinical responses observed are reflective of those in the Phase 3 clinical program and affirm our understanding that Xeljanz is an important option both in combination with methotrexate and as monotherapy for patients who do not respond to or are intolerant to methotrexate.

Regarding safety data, the most commonly reported adverse events for each study arm were upper respiratory tract infections, alanine aminotransferase elevation, nasopharyngitis, urinary tract infections, and nausea. Between treatment arms, the overall rate of adverse events were similar.

Adverse events were seen in 61.4% of the Xeljanz 5mg twice daily + methotrexate group, 58.9% of the Xeljanz 5mg twice daily group, and in 65.5% of Humira 40mg every other week + methotrexate group. Serious adverse events were noted in 7.2% of the Xeljanz 5mg twice daily + methotrexate group, 9.1% of the Xeljanz 5mg twice daily group, and in 6.2% of Humira 40mg every other week + methotrexate group.

Xeljanz andXeljanz XRare Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate. Xeljanz and Xeljanz XR may be used alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

For more information visitXeljanz.com.

Read more:
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study - Monthly Prescribing Reference (registration)

Janssenannounced results from the pivotal Phase 3 GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA(golimumab) in the treatment of active psoriatic arthritis. In GO-VIBRANT, 75.1 percent of patients with active psoriatic arthritis receiving SIMPONI ARIA2 mg/kg achieved at least a 20 percent improvement in arthritis signs and symptoms as measured by the American College of Rheumatology (ACR20) at week 14, the studys primary endpoint, compared with 21.8 percent of patients receiving placebo (P< 0.001). SIMPONI ARIAalso showed significant improvement across all secondary endpoints evaluating improvements in skin symptoms, joint damage and health-related quality of life measures. Data from GO-VIBRANT are being presented for the first time at the Annual European Congress of Rheumatology (EULAR) 2017. SIMPONI ARIAis currentlyunder reviewby the U.S. Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis and the treatment of adults with ankylosing spondylitis. SIMPONI ARIAis approved in the U.S. for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.

Results from the GO-VIBRANT study showed that treatment with intravenous golimumab improved joint and skin symptoms in patients with active psoriatic arthritis, and inhibited the progression of structural damage, which are important treatment goals in the management of this progressive, inflammatory disease, said Arthur Kavanaugh, MD, Professor of Medicine, University of California San Diego, and Chair of the GO-VIBRANT steering committee. Intravenously administered golimumab could represent an important new anti-TNF-alpha therapy for rheumatologists to consider in the treatment of active psoriatic arthritis in the future. Treatment with SIMPONI ARIAat weeks 0 and 4 and every eight weeks thereafter resulted in statistically significant improvements in all secondary endpoints presented below (P< 0.001 for all measures).

At week 14

At week 24

Through week 24, 46.3 percent of SIMPONI ARIA-treated patients and 40.6 percent of placebo-treated patients reported at least one adverse event (AE). Serious AEs were reported by 2.9 percent of patients receiving SIMPONI ARIAvs. 3.3 percent for placebo. Two deaths and two malignancies were reported, all in the placebo group, and one demyelinating event occurred in the SIMPONI ARIAgroup. The most common treatment-emergent type of AE was infection, identified in 20.0 percent of SIMPONI ARIA-treated patients compared to 13.8 percent of placebo-treated patients. There was no opportunistic infection or tuberculosis through week 24. The rate of infusion reactions with SIMPONI ARIAwas less than 2 percent and none were serious or severe.

At Janssen, our commitment to rheumatology began more than two decades ago with discovery, development and approval of the first anti-TNF-alpha therapy, and since then, we have continued to build upon our portfolio of medicines for patients with immune-mediated diseases, said Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. Data from the GO-VIBRANT study demonstrated how SIMPONI ARIA, a product already helping people living with moderately to severely active rheumatoid arthritis, may also help those living with psoriatic arthritis, pending its approval in the U.S.

Additional SIMPONI ARIAdata being presented at EULAR 2017 includes findings from the Phase 3 ankylosing spondylitis GO-ALIVE study:

Continued here:
New Phase 3 Data Shows Golimumab Significantly Improved Arthritis and Skin Manifestations in Patients with Active RA - Drug Discovery &...

The ankylosing spondylitis and psoriatic arthritis markets are growing increasingly crowded, but Novartis now has something not all its rivals can boast: long-term data for its IL-17 med, Cosentyx.

Thursday at the Annual European Congress of Rheumatology in Madrid, the Swiss drugmaker unveiled study results showing its contender could show sustained improvements in signs and symptoms of both maladies.

In one extension trial, at three years, 80% of ankylosing spondylitis patients taking Cosentyx hit the 20 mark on the Assessment of Spondyloarthritis International Society response criteria scale.

And a new analysis of Novartis Future 2 study showed that by the two-year point, 28% of psoriatic arthritis patients treated with Cosentyxalmost all of whom had reported moderate-to-extreme pain or discomfort before starting on the drugfelt no pain or discomfort at all.

RELATED:Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Its good news for Novartis, whose med is currently the only member of the IL-17 crowd to boast indications in ankylosing spondylitis and psoriatic arthritis. Knowing competition was on the way, the company worked to snag those a year after winning Cosentyx initial nod in psoriasis.

Since then, Novartis has been joined by Eli Lillys Taltz and Valeants Siliq, and development of other candidatessuch as Johnson & Johnsons guselkumabis underway. Lilly, for one, currently has Taltz in phase 3 as a treatment for axial spondyloarthritis, an umbrella that includes ankylosing spondylitis.

But its not only IL-17 products competing for a slice of the pie. Pfizer is developing its rheumatoid arthritis pill, Xeljanz, for psoriatic arthritis, and Celgene's psoriasis pill Otezla has a psoriatic arthritis nod, as well. On the ankylosing spondylitis front, J&Js Stelara could eventually challenge Cosentyx, research and consulting firm GlobalData has predicted.

Read this article:
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis - FiercePharma

Johnson & Johnsons Innovation unit has unveiled another clutch of deals and collaborations with industry and academia, as it also shares its molecular library to help fight neglected diseases.

J&Js Innovation unit has more than 300 collaborative pacts to its nameand started the year with 15 more that focused on a biotech NASH deal with Bird Rock Bio, while also bumping up its work on malaria and penning another RNA deal with Synthetic Genomics.

RELATED: J&J in New Year deal mania, takes on NASH candidate with biotech buyout option

Six months down the line and timed to coincide at this years BIO Convention, its at it again, with its R&D unit Janssen inking a multiproject collab with the University of California San Diego School of Medicinefocused on fatty liver disease/obesity.

Plans are in place to work on finding pathways and mechanisms driving disease progression, as well as clinically useful biomarkers, targets and gastric bypass approaches, all of which is designed to find new therapies for NASH, chronic kidney disease (CKD) and other obesity-based conditions.

Projects under this collaboration will include exploration of animal and cell models of NASH and CKD, discovery of mechanisms invoked by bariatric surgery, disease-related biomarkers and novel therapeutic targets, J&J said in a statement.

Building on its blockbuster work in rheumatoid arthritis (RA), and coming as a host of biosimilars line up to erode sales from older meds, Janssen Biotech has also formed a multiyear collaborationand prenegotiated option-to-license agreementwith Monash University to discover and develop next-gen biologics to treat, prevent and intercept RA. As is usual with these deals, dollar terms have not been disclosed.

And building on its work in malaria and other neglected diseases, Janssen has penned pacts aimed at speeding up the discovery of new treatments for tuberculosis, malaria, neglected tropical diseases, and other diseases prevalent in the developing world.

It will help by sharing selected parts of its molecular libraries with governmental biomedical research agenciessuch as the U.S. National Institute of Allergy and Infectious Diseases of the National Institutes of Health and academic centers such as Washington University in St. Louis, the University of California, Berkeley, and the Center for Discovery and Innovation in Parasitic Diseases at the University of California San Diego.

Through WIPO Re:Search, the international research consortium led by the nonprofit BIO Ventures for Global Health and the United Nations World Intellectual Property Organization, Janssen says it will open up segments of its molecule library, which hold a set of 80,000 chemical compounds, to these organizations to help seek out and push on with promising drug candidates.

By working collectively, the global health community can increase and accelerate the potential to achieve major research breakthroughs for the millions of people worldwide who suffer from these devastating diseases, said Wim Parys, M.D., head of R&D Global Public Health at Johnson & Johnson, in a release.Opening our compound libraries and providing our partners access to the research capabilities of the Johnson & Johnson family of companies underscores our commitment to accelerate the pace of innovation to broaden our reach and deepen our impact.

See the original post:
Johnson & Johnson unveils new obesity, arthritis collaborations ... - FierceBiotech

Development of a drug to help those suffering from rheumatoid arthritis may prove to be quite a happy accident for aging individuals with hardening heart valves. Researchers from Vanderbilt University announced promising results in examining a monoclonal antibodys ability to combat aortic valve stenosis.

The results, published June 12 in Circulation, could be an important step toward fighting the condition that affects a quarter of Americans over the age of 65, who previously only had surgical replacement of valves as an option.

Very elderly patients bodies cant handle that, said first author Cyndi Clark, research assistant professor of biomedical engineering at Vanderbilt. I hope to see an earlier treatment option available within the next decade.

The drug, known as SYN0012, appeared to bind to cadherin-11 (CDH-11), a protein that causes the hardening of valve tissue.

The antibody we're working with blocks fibroblasts from becoming the active type that leads to disease. It keeps them from becoming inflamed, said W. David Merryman, associate professor of biomedical engineering at Vanderbilt. "We believe there is potential for using this drug at the first sign of valve disease to prevent the progression. You likely cannot reverse the damage, but we believe the drug can prevent it."

The drug is in human clinical trials for treatment of rheumatoid arthritis. After those are complete, Merryman hopes to gain permission to run clinical trials for uses in heart valve disease. His work is funded by a $5.3 million award from the National Heart, Lung and Blood Institute.

More:
Arthritis drug shows promise in combatting protein that causes aortic valve stenosis - Cardiovascular Business

GETTY

The autoimmune condition is caused by the immune system attacking healthy body tissue.

However, researchers explored whether high body fat and large waist size were a risk factor.

In the study, presented this week to the Annual European Congress of Rheumatology 2017, they found no clear association between rheumatoid arthritis (RA) and being overweight or obese in men.

However, for women, being overweight or obese was linked to a higher likelihood of developing it.

GETTY

This conflicts with previous studies that found an association for both genders between rheumatoid arthritis and being overweight or obese.

This conflicts with previous studies that found an association for both genders.

Dr. Asta Linauskas, lead study author from University Hospital, Aarhus in Denmark, said: One possible explanation for these inconsistencies is that while BMI has been the preferred surrogate measure for being overweight in these studies, BMI only correlates modestly with total amount of body fat and does not accurately reflect fat distribution.

"Our results support an association between the risk of developing RA and three different criteria for being overweight or obese in women.

We believe RA should be included in the list of all the other medical conditions linked to obesity. It would certainly make sense for women with a family history of RA to try to avoid becoming overweight.

Getty

1 of 12

GETTY

In the study, they looked at 54,284 people - 52 per cent women - between the ages of 50 and 64 years at the time of recruitment between 1993 and 1997.

During a median follow up of 21 years, 283 women and 110 men developed RA.

The median time for onset of the condition was seven years.

In the data, a positive slope in women confirmed a direct relationship, but there was no such linear association in men.

GETTY

According to the NHS, other possible risk factors include genetics, hormones and smoking.

As well as joint pain, symptoms can include sweating, a poor appetite and weight loss.

The condition can be difficult to diagnose as many conditions cause joint stiffness and inflammation.

However, once diagnosed, treatment can be used to enable you still stay as active as possible.

Link:
Rheumatoid arthritis: Being overweight might NOT be a risk factor in ... - Express.co.uk

A new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.

The treatment, recently approved by the Food and Drug Administration, is called cooled radio frequency ablation and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that dont make them a good candidate for surgery.

Marketed as "Coolief", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain. Coolief doesnt repair arthritis in the knee, but eases the pain, helping patients go back to activities without discomfort and fewer medications.

What we're changing is the wiring of the knee so we're taking away the pain signal and interrupting it," Dr. Amin Sandeep, a pain specialist at Rush University Medical Center in Chicago who performs the procedure, told NBC News.

One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections. Coolief reduces pain for about to 6 to 12 months, depending on how fast the nerves in the knee regenerate.

Related: Common Knee Surgery May Not Help You

Osteoarthritis can affect any joint when the cartilage wears off over time, often striking big joints like the knee, causing pain, swelling and stiffness. According to the American Academy of Orthopedic Surgeons, nearly 10 million Americans had osteoarthritis of the knee in 2010.

The three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.

But those didn't help Felicia McCloden, a 65-year-old grandmother from outside of Chicago. The excruciating pain in her right knee made simple tasks like grocery shopping impossible.

I had inflammation, swelling, and my knee was like the size of a golf ball, McCloden told NBC News. "The arthritis was so bad that I could barely step down without severe pain.

Because she wasnt eligible for a knee replacement she tried cortisone injections, physical therapy, medications nothing relieved her pain.

"I thought I was going to limp for the rest of my life," she said.

Related: What Really Helps Knee Pain? The Answer May Surprise You

In May, McCloden underwent the Coolief treatment and the result was instant.

I couldn't even imagine first of all, not having the pain," she said. "It erased all of that.

The outpatient procedure typically takes about 40 minutes, is performed with local anesthesia and doesnt require an incision. Instead, doctors use specialized needles that emit radio frequencywaves into the knee. The cost of the treatment is between $2,000 and $4,000. Because it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.

Some of the reported risks from the procedure include bleeding and infection. "Though patients have a risk of the physician hitting the wrong nerve, that is extremely rare in the hands of an experienced professional, Amin said.

Recovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.

For some patients with structural problems of the knee, the procedure won't help, said pain specialist Dr. Edgar Ross, associate professor of anesthesia at Brigham and Womens Hospital.

"But lets say a patient is younger, instead of going for a total knee replacement early, which might have to be repeated later on, Coolief can postpone the need for the total knee replacement," Ross told NBC News.

Coolief can be repeated if necessary, but it's not a permanent solution. While it reduces pain, it can't stop the progression of osteoarthritis.

"While it can delay total knee replacement, knee replacement may still eventually be necessary in a big number of patients," said Dr. Dennis Cardone, associate professor of orthopedic surgery at NYU Langone Medical Center.

Link:
Cool' New Knee Procedure Eases Arthritis Pain Without Surgery - NBCNews.com

Kansas City Star

Watch: Chiefs' Charcandrick West sings to raise awareness for childhood arthritis Kansas City Star Chiefs' running back Charcandrick West has a busy summer ahead as he battles for positioning on the depth chart. But West, who was diagnosed with arthritis at 14 years old, realizes life goes beyond football. So before organized team activities began ...

Continue reading here:
Watch: Chiefs' Charcandrick West sings to raise awareness for childhood arthritis - Kansas City Star